Histone deacetylase inhibitors reduce polyglutamine toxicity
AUTOR(ES)
McCampbell, Alexander
FONTE
The National Academy of Sciences
RESUMO
Polyglutamine diseases include at least nine neurodegenerative disorders, each caused by a CAG repeat expansion in a different gene. Accumulation of mutant polyglutamine-containing proteins occurs in patients, and evidence from cell culture and animal experiments suggests the nucleus as a site of pathogenesis. To understand the consequences of nuclear accumulation, we created a cell culture system with nuclear-targeted polyglutamine. In our system, cell death can be mitigated by overexpression of full-length cAMP response element binding protein (CREB)-binding protein (CBP) or its amino-terminal portion alone. CBP is one of several histone acetyltransferases sequestered by polyglutamine inclusions. We found histone acetylation to be reduced in cells expressing mutant polyglutamine. Reversal of this hypoacetylation, which can be achieved either by overexpression of CBP or its amino terminus or by treatment with deacetylase inhibitors, reduced cell loss. These findings suggest that nuclear accumulation of polyglutamine can lead to altered protein acetylation in neurons and indicate a novel therapeutic strategy for polyglutamine disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=65003Documentos Relacionados
- Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway
- Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
- Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy
- Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase
- Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse